Clinical Trial Update: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients [Phase 1]

View source ↗

Summary

Phase 1 safety study of a recombinant vaccinia virus (JX-594/Pexa-Vec) for refractory pediatric solid tumors. The trial has completed and enrolled patients with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Lymphoma
• Neuroblastoma
• Rhabdomyosarcoma
• Wilms Tumor

Drugs mentioned

• JX-594 (Pexa-Vec)

Snippet

Sponsor: Jennerex Biotherapeutics | Conditions: Neuroblastoma, Rhabdomyosarcoma | Phase 1 | Status: COMPLETED